Sionna Therapeutics financials
$5.15+0.59%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $0.00 |
| Gross profit | $0.00 |
| Gross margin | — |
| Operating income | -$89.0M |
| Net income | -$75.3M |
| Net margin | — |
| Diluted EPS | $-1.88 |
| EBITDA | -$88.3M |
| Operating cash flow | -$66.3M |
| Free cash flow | -$66.7M |
| Diluted shares | 40.0M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $58.5M |
| Short-term investments | $177.4M |
| Total debt | $0.00 |
| Total assets | $326.0M |
| Total liabilities | $19.1M |
| Shareholders' equity | $306.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology